| Trial ID: | L0544 |
| Source ID: | IRCT2017012031423N1
|
| Associated Drug: |
Curcumin
|
| Title: |
Evaluation of influence of Curcumin on non-invasive liver marker`s in patients with nonalcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic fatty liver disease. <br>Fatty (change of) liver, not elsewhere classified;Fatty (change of) liver, not elsewhere classified
|
| Interventions: |
Intervention 1: Control group: Patients in groups of 30 for a period of two months Placebo 2 times a day will be prescribed. Intervention 2: Intervention group: Patients in groups of 30 for a period of two months curcumin(Sinacurcumin; nanomicelles) to 80
|
| Outcome Measures: |
BMI. Timepoint: Before and two months after intervention. Method of measurement: Measuring the weight by Scale and height by Metre.;ALT. Timepoint: Before and two months after intervention. Method of measurement: Serology.;AST. Timepoint: Before and two months after intervention. Method of measurement: Serology.;ALP. Timepoint: Before and two months after intervention. Method of measurement: Serology.;TG. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Total Cholestrol. Timepoint: Before and two months after intervention. Method of measurement: Serology.;HDL. Timepoint: Before and two months after intervention. Method of measurement: Serology.;FBS. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Serum Insulin. Timepoint: Before and two months after intervention. Method of measurement: Serology.;LDL. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Total Bilirubin. Timepoint: Before and two months after intervention. Method of measurement: Serology.;Direct Bilirubin. Timepoint: Before and two months after intervention. Method of measurement: Serology.nan
|
| Sponsor/Collaborators: |
Vice Chancellor for research of Mashhad University of Medical Sciences
|
| Gender: |
All
|
| Age: |
15 years60 years
|
| Phases: |
Phase 2/Phase 3
|
| Enrollment: |
60
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Sealed envelopes.
|
| Start Date: |
22/05/2017
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/24720
|
